- Abstract Number: 2005
Impact of Anti-drug Antibodies on the Efficacy of SEL-212 in Patients with Chronic Gout Refractory to Conventional Therapy
- Abstract Number: 0412
Impact of Approval of Biologic DMARDs on JIA Outcomes in a Single Center
- Abstract Number: 2369
Impact of Baseline Factors on Disease Progression and Apremilast Efficacy in Early Oligoarticular Psoriatic Arthritis
- Abstract Number: 0631
Impact of Baseline Proteinuria Level on Long-term Outcomes in Lupus Nephritis
- Abstract Number: 2209
Impact of Common Infections on Medication Interruptions, Quality of Life, and Disease Flares in Patients with Rheumatoid Arthritis
- Abstract Number: 1146
Impact of COVID-19 on Myositis Testing Trends
- Abstract Number: 1437
Impact of Early Diagnosis in Patients with Axial Spondyloarthritis on Arterial Stiffness Progression
- Abstract Number: 1124
Impact of Genetic Predisposition for Type 2 Diabetes in Plasma Glucose Levels After the Administration of a High Dose of Systemic Glucocorticoids
- Abstract Number: 2148
Impact of Hip Fractures in the Elderly Population: Functional Status, Readmission, and One-Year Mortality
- Abstract Number: 0664
Impact of Hydroxychloroquine and Belimumab on Early Glucocorticoid Reduction in New-Onset Systemic Lupus Erythematosus: A Retrospective Analysis of Risk and Protective Factors
- Abstract Number: 2429
Impact of Hydroxychloroquine Level on ECG QTC Interval in Patients with Rheumatic Systemic Autoimmune Diseases: A Real-life Study
- Abstract Number: 1319
Impact of Illness Cognition and Self-Esteem on Quality of Life in Reproductive-Age Women with Autoimmune Rheumatic Diseases
- Abstract Number: 2144
Impact of Immunogenicity on Clinical Outcomes in Postmenopausal Women with Osteoporosis: Results from a Randomized Controlled Phase 3 Study to Compare CT-P41 (Proposed Denosumab Biosimilar) and Reference Denosumab
- Abstract Number: 1582
Impact of Immunosuppressive Treatment on Development and Survival in Systemic Sclerosis Associated Pulmonary Arterial Hypertension (SSc-PAH)
- Abstract Number: 2653
Impact of Insurance on Time to Biological Drug (bDMARD) Initiation and Inactive Disease Achievement in Patients with Juvenile Idiopathic Arthritis
- « Previous Page
- 1
- …
- 87
- 88
- 89
- 90
- 91
- …
- 181
- Next Page »